Prelude announced it has decided to pause the clinical development of its SMARCA2 degrader program. The decision to pause was based on a comprehensive review of clinical data generated to date and the Company’s assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics announces publication of abstracts for ASH meeting
- Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
- Prelude Therapeutics Appoints Katina Dorton to Board
- Prelude Therapeutics appoints Katina Dorton to board of directors
- Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating